CTOs on the Move


 
Biocon Limited, publicly listed in 2004, is India`s largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.biocon.com
  • 485 Hwy 1 (S) Suite B 305
    Iselin, NJ USA 08830
  • Phone: 732.636.2950

Executives

Name Title Contact Details

Similar Companies

Santen

At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.

automation X

automation X is a Vienna, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PharMEDium Healthcare Corporation

PharMEDium is an organization that has established an outstanding reputation for quality and customer service in the healthcare marketplace. Credit for this goes to everyone in the organization. We hope you, too, will find satisfaction and take pride in

Protemix

Protemix is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XORTX

XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.